{"id":3260,"date":"2021-03-26T00:00:00","date_gmt":"2021-03-25T23:00:00","guid":{"rendered":"https:\/\/www.neolifesalud.com\/a-protein-that-fights-obesity\/"},"modified":"2021-03-26T00:00:00","modified_gmt":"2021-03-25T23:00:00","slug":"a-protein-that-fights-obesity","status":"publish","type":"post","link":"https:\/\/www.neolifesalud.com\/en\/blog\/nutrition\/a-protein-that-fights-obesity\/","title":{"rendered":"A Protein that Fights Obesity"},"content":{"rendered":"
\n

Obesity is a growing epidemic and one of the leading causes of preventable death worldwide. Unhealthy eating habits and a sedentary lifestyle are most responsible for weight gain and fat accumulation.<\/strong><\/h1>\n

Obesity is a disease that affects over 650 million people worldwide. It\u2019s a global public health problem, and it costs over 150 billion annually to treat acute and chronic obesity conditions. Recently, a promising study has been published, which has demonstrated the action mechanism and preclinical efficacy of a protein called BAM15, effective in the treatment of obesity and related metabolic disorders.<\/p>\n

Alejandro Monz\u00f3 – Neolife Nutrition and Nursing Unit<\/em><\/p>\n

\n

BAM15 is a protein that prevents weight gain and fat accumulation, while reducing blood sugar levels<\/strong><\/p>\n

Advances in small molecule screening and biochemical engineering have led to a renewed interest in mitochondrial agents directed towards the treatment of metabolic disease<\/strong>, such as obesity. Currently, only four medicines (orlistat, phentermine-topiramate, naltrexone-bupropion, and liraglutide) are approved for the treatment of obesity<\/strong> (2, 3). However, they are limited when it comes to effectively providing long-term weight<\/strong> loss.<\/p>\n

Their limitations are due, in part, to the difficulty in identifying bioactive compounds<\/strong> with a wide therapeutic range that address the multifactorial causes and effects of obesity. Recently, the scientific journal EMBO Molecular Medicine<\/em> published research that reveals a very promising step in addressing obesity. The protein BAM15<\/strong>, a mitochondrial proton translocator, may be used to treat this chronic, non-communicable disease (3).<\/p>\n

In general, existing medications work by reducing appetite or calories absorbed after food<\/strong> intake (2). The protein BAM15<\/strong> differs greatly from these drugs, as its potential lies in decreasing the efficiency of cellular mitochondria, resulting in their “burning” more energy (3). Mitochondria are the cellular organelles responsible for supplying most of the energy needed for cellular activity, acting as power plants and releasing ATP, which is the fuel for most cellular processes (4).<\/p>\n

Researchers have shown in trials with mice that those who received BAM15<\/strong> burned more calories and therefore had a lower weight gain than the mice in the control group (3). After obtaining these results, the authors noted that this protein may be used to treat obesity, in addition to other diseases related to it, such as diabetes<\/strong>, liver disease<\/strong>, and some forms of cancer<\/strong>. Additionally, the study shows numerous other benefits of this protein (Figure 1):<\/p>\n